Sunday, 22 April 2018 - 7:44
  • it
  • de
  • en
  • fr

Autism

New developments for Roche’s novel autism therapy

FDA has granted Breakthrough Therapy designation to Roche’s RG7314 investigational therapy (balovaptan), developed by the Switzerland-based group for the treatment of autism. Balovaptan is a V1A receptor antagonist, which has already shown efficacy against autism in various clinical trials. Roche’s…

New therapeutic indications for metformin

Metformin, a member of the biguanide family, is a drug for the treatment of type-2 diabetes. It is constantly obtaining new therapeutic indications. Last year, research suggested that metformin prevents the onset of cancer through a process which fortifies epithelial…